Welcome to our dedicated page for Treace Medical Concepts news (Ticker: TMCI), a resource for investors and traders seeking the latest updates and insights on Treace Medical Concepts stock.
Treace Medical Concepts, Inc. is a leading orthopaedic medical device company specializing in innovative solutions for the surgical management of bunion deformities. With a commitment to excellence, the company brings breakthrough technologies to the high-growth $1.1 billion US market for foot and ankle surgical products.
Treace's flagship product, the Lapiplasty® 3D Bunion Correction™ procedure, addresses the root cause of bunions by correcting all planes of the deformity. This patented procedure not only improves patient outcomes but also allows for a quicker return to an active lifestyle.
The company operates as a single segment, focusing on the design, manufacturing, and marketing of medical devices for physicians, surgeons, ambulatory surgery centers, and hospitals. Their mission is to assist foot and ankle physicians in enhancing patient outcomes and reducing healthcare costs, while also providing a rewarding experience for their employees and exceptional returns for shareholders.
In recent news, Treace Medical Concepts announced their participation in the upcoming J.P. Morgan Healthcare Conference, showcasing new SpeedPlate™ configurations, and the full commercial release of the Micro-Lapiplasty™ System. Additionally, they have initiated a limited clinical release of the Mini-Adductoplasty™ System and RedPoint™ Patient-Specific Instrumentation. The company also focuses on educational outreach to build awareness and reduce stigma around bunion deformities.
Treace Medical Concepts has also partnered to support pickleball players with bunions and related midfoot deformities, helping them to 'get back on their feet' and onto the court. Such initiatives highlight Treace's dedication to improving the lives of individuals affected by foot health issues.
Treace Medical Concepts (TMCI) reported its Q4 and full-year 2024 financial results, showing continued growth and improved profitability. Q4 2024 revenue increased 10% to $68.7 million, while full-year revenue grew 12% to $209.4 million.
The company significantly reduced its Q4 net loss to ($0.5) million from ($6.3) million in Q4 2023, with Adjusted EBITDA improving 322% to $11.1 million. Full-year 2024 net loss was ($55.7) million.
Key operational highlights include:
- Added 280 new active surgeons in 2024, reaching 3,135 total (10% increase)
- Expanded patent portfolio to 97 granted patents
- Entered high-volume osteotomy market with Nanoplasty™ and Percuplasty™ Systems
The company provided 2025 revenue guidance of $224-230 million (7-10% growth) and expects to achieve breakeven Adjusted EBITDA for full-year 2025.
Treace Medical Concepts (NasdaqGS: TMCI), a medical technology company specializing in surgical treatments for bunions and midfoot deformities through its Lapiplasty® and Adductoplasty® Procedures, has announced it will release its fourth quarter and full-year 2024 financial results after market close on February 27, 2025.
The company will host a conference call with management at 4:30 pm ET on the same day to discuss the results. Interested investors can register to receive dial-in numbers and a unique pin to participate and ask questions. A live and archived webcast will be available on the company's investor relations website.
Treace Medical Concepts (NASDAQ: TMCI) has announced the successful completion of first surgical cases using its new SpeedAkin™ Anatomic Compression Implant. This implant expands the capabilities of their SpeedPlate™ fixation platform, specifically designed for Akin osteotomies - corrective procedures commonly performed during bunion surgery.
The SpeedAkin™ implant features dynamic titanium compression to stabilize Akin osteotomies during healing, offering an anatomically contoured fixation solution that eliminates potential nickel allergy reactions associated with nitinol staples. This development complements Treace's existing bunion treatment portfolio, which includes their flagship Lapiplasty® and Adductoplasty® Procedures.
Treace Medical Concepts (NASDAQ: TMCI) has released preliminary, unaudited financial results for Q4 and full-year 2024. The company reported preliminary Q4 revenue between $68.4-68.8 million, representing approximately 10% growth compared to Q4 2023. Full-year 2024 preliminary revenue reached $209.0-209.4 million, showing roughly 12% growth year-over-year and aligning with previous guidance of $204-211 million.
The company added approximately 280 new active surgeons in 2024, ending the year with about 3,135 active surgeons, a 10% increase from 2023. This represents approximately 31% of the estimated 10,000 U.S. surgeons performing bunion surgery. The company plans to provide 2025 financial guidance during its Q4 2024 earnings call scheduled for February 27, 2025.
Treace Medical Concepts (NasdaqGS: TMCI), a pioneer in bunion and midfoot deformity surgical treatments through its Lapiplasty® and Adductoplasty® Procedures, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference.
CEO John T. Treace will deliver a presentation on Tuesday, January 14, 2025, at 9:00 am PT. The company will provide a live webcast of the fireside chat, which will be accessible through their investor relations website at https://investors.treace.com/.
The company maintains regular updates for investors through their website's Investor Relations section at www.treace.com, where important information is routinely posted for stakeholders and potential investors.
Treace Medical Concepts (TMCI) announced the market release of its Percuplasty™ Percutaneous 3D Bunion Correction® System, marking the company's second entry into the metatarsal osteotomy segment. This segment represents approximately 70% of the 450,000 annual bunion surgeries in the U.S.
The Percuplasty™ System offers a minimally invasive approach through percutaneous incisions, designed to minimize post-operative pain and accelerate recovery. This launch follows the Nanoplasty™ System release, expanding Treace's portfolio in the $5B+ US bunion market. Full commercialization is expected in the second half of 2025.
Treace Medical Concepts (NASDAQ: TMCI) has announced the successful completion of first surgical cases using their new SpeedPlate™ MicroQuad™ implants. This innovation expands their SpeedPlate™ platform, designed for fast titanium compression fixation in bunion and midfoot deformity treatments.
The MicroQuad™ implant features an anatomic design with multiple fixation points on each joint side, delivering dynamic compression with rotational stability through a one-inch incision. The company plans a full market release in the first half of 2025. Initial surgical cases were performed by Dr. William T. DeCarbo, who praised the implant's anatomic contour and rotational stability through minimal incision.
Treace Medical Concepts (NASDAQ: TMCI) announced the successful implementation of IntelliGuide™ PSI technology with the Adductoplasty® System, marking a significant advancement in midfoot deformity correction. This system is the first patient-specific cut guide system available in the U.S. for bunion and midfoot deformity correction.
The technology uses AI-enabled software to convert patient CT-scans into pre-operative surgical plans and creates 3D-printed cut guides customized to each patient's deformity. The company has initiated a market release of IntelliGuide™ PSI for the Adductoplasty® Procedure, with full market release expected in the first half of 2025. Notably, midfoot deformities may affect up to 30% of bunion patients.
Treace Medical Concepts (NasdaqGS: TMCI), a medical technology company specializing in surgical treatments for bunions and midfoot deformities through its Lapiplasty® and Adductoplasty® Procedures, has appointed Guy Guglielmino as Chief Commercial Officer. In this new role, Guglielmino will lead the company's commercial efforts and drive innovation, product commercialization, and growth. He joins Treace with extensive medical technology industry experience, most recently serving as President, Recovery Sciences at Enovis, with previous senior Marketing roles at Wright Medical and Bausch + Lomb.
Treace Medical Concepts (NasdaqGS: TMCI), a medical technology company focused on surgical treatment of bunions and midfoot deformities through its Lapiplasty® and Adductoplasty® Procedures, announced its participation in the Stifel 2024 Healthcare Conference. The company's CEO John T. Treace and CFO Mark L. Hair will participate in a fireside chat on November 19, 2024, at 8:00 am ET. A live webcast and replay will be available on the company's investor relations website.
FAQ
What is the current stock price of Treace Medical Concepts (TMCI)?
What is the market cap of Treace Medical Concepts (TMCI)?
What does Treace Medical Concepts, Inc. specialize in?
What is the Lapiplasty® 3D Bunion Correction™ procedure?
What recent products has Treace Medical Concepts released?
How does Treace Medical Concepts support the foot and ankle surgical market?
When is Treace Medical Concepts presenting at the J.P. Morgan Healthcare Conference?
What is Treace's focus regarding patient outcomes?
Who are the primary customers of Treace Medical Concepts?
What ethical standards does Treace Medical Concepts adhere to?
What is the company’s mission?
How is Treace Medical Concepts involved in community outreach?
